Compass Therapeutics (NASDAQ:CMPX) Trading Down 6.8% – Time to Sell?

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s share price traded down 6.8% during trading on Thursday . The company traded as low as $5.67 and last traded at $5.6280. 1,886,479 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 2,872,656 shares. The stock had previously closed at $6.04.

Wall Street Analysts Forecast Growth

CMPX has been the topic of several research reports. Cantor Fitzgerald assumed coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “overweight” rating on the stock. Citigroup assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Leerink Partnrs raised shares of Compass Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. Finally, Raymond James Financial reissued an “outperform” rating and set a $9.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Stock Down 4.2%

The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -12.86 and a beta of 1.45. The company’s fifty day simple moving average is $5.13 and its 200 day simple moving average is $3.99.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. As a group, analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC increased its stake in shares of Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after purchasing an additional 6,951,666 shares during the period. Vivo Capital LLC grew its holdings in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Vanguard Group Inc. increased its position in Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after buying an additional 2,212,794 shares during the period. Adage Capital Partners GP L.L.C. increased its position in Compass Therapeutics by 11.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after buying an additional 449,868 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Compass Therapeutics by 280.4% during the third quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after buying an additional 2,386,367 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.